Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.
Oriana MandolfoHelen ParkerÈlia AguadoYuko Ishikawa LearmonthAi Yin LiaoClaire O'LearyStuart EllisonGabriella ForteJessica TaylorShaun WoodRachel SearleRebecca J HolleyHervé BoutinBrian W BiggerPublished in: EMBO molecular medicine (2024)
Mucopolysaccharidosis type IIIA (MPS IIIA) is a rare paediatric lysosomal storage disorder, caused by the progressive accumulation of heparan sulphate, resulting in neurocognitive decline and behavioural abnormalities. Anecdotal reports from paediatricians indicate a more severe neurodegeneration in MPS IIIA patients, following infection, suggesting inflammation as a potential driver of neuropathology. To test this hypothesis, we performed acute studies in which WT and MPS IIIA mice were challenged with the TLR3-dependent viral mimetic poly(I:C). The challenge with an acute high poly(I:C) dose exacerbated systemic and brain cytokine expression, especially IL-1β in the hippocampus. This was accompanied by an increase in caspase-1 activity within the brain of MPS IIIA mice with concomitant loss of hippocampal GFAP and NeuN expression. Similar levels of cell damage, together with exacerbation of gliosis, were also observed in MPS IIIA mice following low chronic poly(I:C) dosing. While further investigation is warranted to fully understand the extent of IL-1β involvement in MPS IIIA exacerbated neurodegeneration, our data robustly reinforces our previous findings, indicating IL-1β as a pivotal catalyst for neuropathological processes in MPS IIIA.
Keyphrases
- poor prognosis
- drug induced
- liver failure
- oxidative stress
- cerebral ischemia
- high fat diet induced
- end stage renal disease
- respiratory failure
- multiple sclerosis
- emergency department
- immune response
- chronic kidney disease
- white matter
- toll like receptor
- stem cells
- intensive care unit
- binding protein
- ejection fraction
- inflammatory response
- blood brain barrier
- machine learning
- resting state
- gold nanoparticles
- electronic health record
- peritoneal dialysis
- patient reported outcomes
- type diabetes
- early onset
- hepatitis b virus
- adverse drug
- room temperature
- nuclear factor
- induced apoptosis
- acute respiratory distress syndrome
- artificial intelligence
- reduced graphene oxide
- carbon dioxide
- mechanical ventilation